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Bleomycin hydrolase (BLMH) is a neutral cysteine
aminopeptidase that has been ascribed roles in
many physiological and pathological processes, yet
its primary biological function remains enigmatic. In
this work, we describe the results of screening of a
library of fluorogenic substrates to identify non-natu-
ral amino acids that are optimally recognized by
BLMH. This screen identified several substrates
with kcat/KM values that are substantially improved
over the previously reported fluorogenic substrates
for this enzyme. The substrate sequences were
used to design activity-based probes that showed
potent labeling of recombinant BLMH as well as
endogenously expressed BLMH in cell extracts,
and in intact cells. Importantly, we identify potent
BLMH inhibitors that are able to fully inhibit endoge-
nous BLMH activity in intact cells. These probes and
inhibitors will be valuable new reagents to study
BLMH function in cellular and animal models of hu-
man diseases where BLMH is likely to be involved.
INTRODUCTION
Bleomycin hydrolase (BLMH) is a cysteine aminopeptidase that
is ubiquitously expressed in mammalian tissue (Bro¨mme et al.,
1996). BLMH was initially discovered for its ability to inactivate
bleomycin (Umezawa et al., 1972; Schwartz et al., 1999), a
drug used extensively to treat cancer. BLMH is a cytosolic
neutral protease with a barrel-like structure composed of six
monomers of 50 kDa each (Bro¨mme et al., 1996; O’Farrell
et al., 1999). The active sites of BLMH are located within the bar-
rel (Hibino et al., 2013). After expression, the C terminus of the
protein undergoes self-cleavage yielding an enzyme with
broad-specificity aminopeptidase activity (Joshua-Tor et al.,
1995; Zheng et al., 1998). While the physiological roles of
BLMH remain obscure, it has been suggested to be important
in several physiological and pathological processes. BLMH null
mice have reduced neonatal survival, brain pathologies (Mon-
toya et al., 2007), and a dermatitis phenotype. BLMH is involved
in the production of free amino acids as moisturizing agents inChemistry & Biology 22, 995the skin (Kamata et al., 2009), and therefore plays an important
role in maintaining epidermal integrity (Kamata et al., 2011).
BLMH has also been shown to play a role in peptide trimming
downstream of the proteasome, and thus has a role in the
production of peptides for antigen presentation (Stoltze et al.,
2000; Kim et al., 2009); however, this role seems to be redundant
(Towne et al., 2007).
In addition to its aminopeptidase activity, BLMH has the ability
to hydrolyze homocysteine lactone, a reactive metabolite pro-
duced from methionine, which causes protein damage and
hyperhomocysteinemia and is implicated in multiple human
diseases, including Alzheimer’s disease. BLMH is implicated in
protection against homocysteine toxicity (Zimny et al., 2006;
Borowczyk et al., 2012). However, recent data showing that
another enzyme exists with higher homocysteine lactonase ac-
tivity has called into question the role for BLMH in homocysteine
detoxification (Marsillach et al., 2014). BLMHpolymorphisms are
also associated with sporadic Alzheimer’s disease (Montoya
et al., 1998; Papassotiropoulos et al., 2000). Ectopic expression
of BLMH increases processing of amyloid precursor, suggesting
a regulatory role for BLMH in the secretion of amyloid precursor
protein and b-amyloid, which are major components of Alz-
heimer’s disease-associated plaques (Lefterov et al., 2000,
2001). However, other studies have shown reduced homocyste-
ine lactonase activity in brains of Alzheimer patients that corre-
lated with a reduction in BLMH levels, thus suggesting a protec-
tive role for BLMH (Suszynska et al., 2010).
At present, BLMH aminopeptidase activity has only been
measured using fluorogenic substrates (Bro¨mme et al., 1996;
Zimny et al., 2006). While these substrates provide a relatively
rapid and simple readout of enzyme activity, the resulting data
are often difficult to interpret because other aminopeptidases
are likely to be active toward the reported substrates (Rut
et al., 2015). Activity-based probes circumvent this problem by
covalently attaching to target enzymes, allowing direct identifi-
cation and quantification of enzyme activity (Sanman andBogyo,
2014). Furthermore, by screening substrate libraries of increased
diversity, it should be possible to identify sequences that are
optimized for BLMH and not cleaved by other aminopeptidases.
In this article, we present a screen of a diverse substrate library
made up of both natural and non-natural amino acids to identify
optimal binding elements for BLMH. Using this approach we
were able to design selective substrates, activity-based probes,
and inhibitors for BLMH. These reagents can be used for
biochemical studies of the purified enzyme as well as to monitor–1001, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 995
Figure 1. Screening of a Diverse Fluoro-
genic Substrate Library
(A) Diagram of the fluorogenic substrate library
screening approach.
(B) Ranking of the top BLMH substrates ordered by
kcat/KM values. The substrates containing Lys(2-
Cl-Cbz) and Cys(Bn) are effective, with activities
that are substantially higher than the best natural
amino acid.and inhibit the endogenous protease target in cellular extracts,
intact cells, and potentially whole organisms.
RESULTS
We screened a hybrid tailored amino acid substrate library that
was recently described and used to find highly efficient sub-
strates of a number of aminopeptidases (Drag et al., 2010; Rut
et al., 2015). This library is made up of a diverse set of natural
and non-natural amino acids linked to a fluorogenic reporter
that provides a signal when the substrate is cleaved by a prote-
ase. Because bleomycin hydrolase is an aminopeptidase, we
screened the library of single amino acid-ACC (7-amino-4-car-
bamoylmethylcoumarin) substrates against the recombinant
protease (Figure 1A). Interestingly, this screen identified non-nat-
ural amino acid-containing substrates that had kcat/KM values
greater than the best natural amino acid, methionine (Figure 1B).
The top two substrates that we chose for further development
into inhibitors and active site probes were Lys(2-Cl-Cbz)-ACC
and S-benzylated cysteine.
To design activity-based probes, we choose electrophiles that
would covalently label the active site nucleophile, but that also al-
lowed incorporation of a tag that would not interfere with the free
aminogroup required for aminopeptidase recognition. Therefore,
we initially used the vinyl sulfone, since this electrophile has been
extensively applied to probes of cathepsins and also the protea-
some (Verdoes et al., 2006; Yuan et al., 2006). We synthesized a
reagent that allows introduction of a vinyl sulfone equipped with
an azide via the Horner-Wadsworth-Emmons (HWE) reaction
(Figure 2A). Diethyl (iodo)methylphosphonate was reacted with
4-aminothiophenol sodium salt to yield aminothioether 1. We996 Chemistry & Biology 22, 995–1001, August 20, 2015 ª2015 Elsevier Ltd All rights reservethen chloroacetylated the amine group in
1 and performed a subsequent substitu-
tion reaction to generate azide 2. Oxida-
tion of the thioether yielded sulfone 3,
which can be used as a general reagent
to make vinyl sulfone probes with a Click
handle.We converted commercially avail-
able Boc-Lys(2-Cl-Cbz)-OH (4a) andBoc-
Cys(Bn)-OH (5a) to the corresponding
Weinreb amides and reduced them to
their respective aldehydes (4c and 5c),
and reacted in the HWE olefination reac-
tion to yield the azide-labeled phenyl vinyl
sulfone inhibitors 4d and 5d. We obtained
the final Cy5 modified activity-based
probes WL1256 and WL1259 using Click
chemistry (Figure 2A).To test the newly synthesized probes we incubated recombi-
nant BLMH (rBLMH) with increasing concentrations of each
probe, then measured labeling by SDS-PAGE analysis followed
by scanning of the gel for fluorescent-labeled protein (Figure 2B).
The labeling confirmed that both probes efficiently labeled the
recombinant protein, as indicated by the presence of a doublet
of 52 kDa corresponding to the expected size of rBLMH. The
appearance of multiple labeled species is likely due to autopro-
cessing of BLMH, as has been previously described (Zheng
et al., 1998). We next tested the limit of sensitivity of the probes
by labeling with a set probe concentration (1 mM) and decreasing
the amount of the rBLMH in the labeling reaction (Figure 2C).
Ultimately, the probe WL1259 showed the most potent labeling
of the target, and was therefore used for validation studies tar-
geting the endogenously expressed enzyme.
To confirm that our optimal probeWL1259was a viable tool for
the study of BLMH function, we performed probe labeling
studies in lysates from fibroblasts derived from wild-type (WT)
and BLMH knockout (KO) mice (Figure 2D). Importantly, these
results confirmed that the probe labeled a protein of the ex-
pected size of 52 kDa in WT lysate that was confirmed to be
native BLMH due to its absence in the KO cell lysate. We
observed similar results when the probe was used to label intact
fibroblast cells derived fromWT and BLMH KOmice (Figure 2E).
These data confirmed that the probe was able to enter cells and
label the native BLMH.
Given the success of the activity-based probes in both lysates
and intact cells, we used the same general scaffolds to generate
inhibitors of BLMH that could be used to block its function in vivo.
We initially synthesized phenyl vinyl sulfone derivatives of
Lys(2-Cl-Cbz) and Cys(Bn), as these most closely matched thed
Figure 2. Synthesis and Evaluation of BLMH Probes Based on the Library Screening Result
(A) Synthesis scheme for the azide-intermediate and final Cy5-labeled probes.
(B) Labeling of 1 mg rBLMH over a range of probe concentrations. Samples were analyzed by SDS-PAGE followed by scanning of the gel using a flatbed laser
scanner to detect the Cy5 signal.
(C) Labeling of decreasing amounts of rBLMH using 1 mM of each of the two primary Cy5 probes.
(D) Assessment of BLMH labeling by the selected probe,WL1259 inwild-type (WT) andBLMH knockout (KO) fibroblast lysates. rBLMH is shown in the first lane as
a standard, but appears as a slightly higher molecular weight than the native enzyme due to the presence of HIS6 tag.
(E) Intact WT and BLMH KO cells were incubated with WL1259 (10 mM) for 3 hr at 37C, then cells were lysed and analyzed by SDS-PAGE as in (D).
The location of BLMH is indicated by a star and is only visible in the WT cells treated with the probe.activity-based probes WL1256 and WL1259. We also synthe-
sized the methyl sulfone versions of the compounds to see
whether the smaller methyl group would reduce steric hindrance
in the active site and result in greater potency. Both classes of
vinyl sulfone compounds were generated using the same chem-
istry as described for the probe synthesis (Bogyo et al., 1997).
We also synthesized the acyloxymethyl ketone (AOMK) and phe-
noxymethyl ketone (PMK) version of the lead compounds, as
these two electrophiles have been extensively used to targetChemistry & Biology 22, 995cysteine proteases (Powers et al., 2002; Kato et al., 2005; Deu
et al., 2010). The synthesis of all the potential BLMH inhibitors
is shown in Figure 3A (Wang et al., 2004). To measure the inhib-
itory potencies of the inhibitors, we used a fluorogenic substrate
assay with the reported BLMH substrate Met-AMC and rBLMH
(Figure 3B). We found that while the original vinyl sulfone com-
pounds had overall good potencies, the AOMK and PMK were
more potent inhibitors of BLMH by several orders of magnitude
(Figure 3C). These data confirm that our chosen scaffold can–1001, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 997
Figure 3. Synthesis and Evaluation of BLMH Inhibitors
(A) Synthesis of six inhibitors for BLMH containing multiple different cysteine-reactive electrophiles.
(B) Fluorogenic substrate assay using rBLMH to determine the IC50 of inhibitors. Fluorogenic substrate experiments were performed in triplicate for each point
and were normalized. Error bars represent SEM.
(C) Calculated IC50 and ki values for the BLMH inhibitors. ki values were derived from curve fitting of the normalized data and are presented as the average ± SD.
998 Chemistry & Biology 22, 995–1001, August 20, 2015 ª2015 Elsevier Ltd All rights reserved
Figure 4. Inhibition of Endogenous BLMH in Intact Cells Using the Optimized Inhibitors
Embryonic fibroblast cells derived from wild-type (WT) and BLMH knockout (KO) mice were incubated with inhibitors at the indicated concentrations for 3 hr at
37C. Cells were washed and lysed, and the lysate incubated with 1 mMWL1259 for 1 hr at 37C. Samples were analyzed by SDS-PAGE followed by scanning of
the gel by a flatbed laser scanner to observe fluorescence. The box indicates the location of native BLMH that is absent in the knockout (KO) cells.be used to yield highly potent inhibitors that are effective in the
low nanomolar concentration range.
As a final test of potency and cell permeability, we treated
intact mouse embryonic fibroblasts (MEF) or BLMH KO mouse
fibroblasts with a range of doses of each inhibitor. We then lysed
cells and labeled them with WL1259, and measured residual
activity of the native BLMH enzyme by SDS-PAGE analysis (Fig-
ure 4). We found that all of the vinyl sulfones were able to pene-
trate cells and completely inhibit BLMH, but only at micromolar
concentrations, consistent with the measured potencies of
the compounds against the recombinant enzyme. The AOMK
(WL911) and PMK (WL920) derivatives, on the other hand,
were able to completely block activity of the native BLMH at
mid to high nanomolar concentrations. Thus, we have identified
a class of highly potent inhibitors of this enigmatic protease that
can be used on intact cells to block enzyme activity and allow
studies of protease function.
SIGNIFICANCE
Although BLMH has been studied for many years, chemical
tools to study its function have not been reported. Here,
we describe activity-based probes and potent cell-perme-
able inhibitors of BLMH. Given that this enzyme has been
postulated to be involved in many physiological processes
important in human diseases, such as antigen processing,
homocysteine lactone detoxification, and Alzheimer’s dis-
ease, the inhibitors and probes presented here will be highly
valuable reagents for further study of BLMH, and can beChemistry & Biology 22, 995used to shed light on its still enigmatic primary biological
functions.
EXPERIMENTAL PROCEDURES
Synthesis of Inhibitors and Probes
Detailed methods and compound characterization for all inhibitors and activ-
ity-based probes can be found in the Supplemental Materials and Methods
section.
Cloning, Expression, and Purification of rBLMH
Details regarding cloning, expression, and purification of rBMLH can be found
in the Supplemental Information.
Screening of Fluorescent Substrates
BLMH was assayed in 100 mM Tris-HCl (pH 7.5), 1 mM EDTA, and 1 mM DTT.
Assays were performed at 37C and enzyme was incubated at 37C for
30 min before adding substrate. Screening of the library was carried out at
2 mM substrate concentration, with 20 nM enzyme. Release of fluorophore
was monitored continuously with excitation at 355 nm and emission at
460 nm for 30–45 min, and the linear portion of the progress curve was
used to calculate velocity. All experiments were repeated at least three times.
Analysis of the results was based on total relative fluorescence units for each
substrate, setting the highest value to 100% and adjusting the other results
accordingly.
Determination of Kinetic Parameters kcat, KM, and kcat/KM
Enzyme assay conditions were as follows: 100-ml reaction with eight different
substrate concentrations. Release of ACC fluorophore was monitored as
above. Absolute ACC concentrations were calculated by the hydrolysis of
three independent ACC-coupled substrates at known concentration, and
average value was determined. Concentration of DMSO in the assay was
less than 1%.–1001, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 999
Fluorogenic Substrate Assay
BLMH activity wasmeasured in black 96-well plates (n = 3). rBLMH (1 nM) was
incubated with inhibitors (1003 DMSO stock) in 100 mM Tris (pH 7.5), 1 mM
EDTA, and 1 mM DTT for 1 hr at 37C. Substrate (100 mM Met-AMC) was
added, and 7-amino-4-methylcoumarin (AMC) fluorescence was monitored
every minute for 45 min at 37C using a Biotek plate reader. Half-maximal
inhibitory concentration (IC50) values were calculated using Graphpad Prism.
ki values were calculated using the formula v/v0 = exp(ki[I]t).
BLMH KO Mouse Generation
KO mice were bred from frozen heterozygous embryos obtained from Jack-
son. The deletion of the BLMH gene was confirmed by genotyping, and loss
of protein expression was confirmed by western blot. All animal care and
experimentation was conducted in accordance with current NIH and Stanford
University Institutional Animal Care and Use Committee guidelines.
Labeling Experiments in Cell Lysate
Mouse immortalized fibroblasts andmouse BLMH KO immortalized fibroblasts
were cultured on DMEM (Gibco) supplemented with 10% fetal calf serum
(Gibco), 100 units/ml penicillin, and 100 mg/ml streptomycin (Gibco) in a 5%
CO2 humidified incubator at 37
C. Cells were harvested, washed twice with
PBS, and permeated in lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl,
20 mM MgCl2, 0.5% NP-40, 2 mM DTT) for 20 min on ice and centrifuged at
16,100 relativecentrifugal force for20minat 4C.Thesupernatantwascollected
and the protein content determined by bicinchoninic acid (BCA) assay (Pierce).
Total lysate (15 or 10 mg total protein) was incubated with the inhibitors (103 so-
lution inDMSO) for 1 hr at 37C.Reactionmixtureswereboiled in Laemmli buffer
containing b-mercaptoethanol for 3 min before being resolved by 15% SDS-
PAGE. In-gel detection of fluorescently labeled proteins was performed directly
in the wet gel slabs on the Typhoon Variable Mode Imager (Amersham Biosci-
ences) using the Cy3/Tamra settings (lex 532 nm, lem 560 nm) for WL1189
andWL1192, orCy5 settings (lex 650nm,lem670nm) forWL1256andWL1259.
Labeling/Inhibition Experiments in Living Cells
Cells (50,000) were seeded and grown overnight. Stock solutions of inhibitors
or probes (1003) were added to 0.5ml ofmedium and the cells were incubated
for 3 hr at 37C. Cells were harvested and washed twice with PBS, and lysate
was prepared as described above. The protein content was determined by
BCA assay (Pierce). For cells labeled with probe, the lysate was immediately
boiled in Laemmli sample buffer and resolved as described above. Lysates
(20 mg total protein, diluted with lysis buffer) from the inhibitor-treated cells
were labeled with 1 mMprobe D for 1 hr at 37C, and boiled in Laemmli sample
buffer and resolved as described above. Staining of the gel with Coomassie
brilliant blue was used to confirm equal protein loading.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Materials and Methods and
can be found with this article online at http://dx.doi.org/10.1016/j.chembiol.
2015.07.010.
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